Literature DB >> 8482277

A regional experience of red cell aplasia.

J A Kynaston1, N C West, M M Reid.   

Abstract

The incidence and current management of red cell aplasia in children was determined from a retrospective survey of haematologists and paediatricians in the northern health region of England over a 7-year period. Thirty-three children were diagnosed: 4 had Diamond Blackfan anaemia, 22 transient erythroblastopenia of childhood, and 7 parvovirus B19 aplasia, with annual incidences of 1, 5 and 2 per 1,000,000 children respectively. Many were over-investigated. Three with Diamond Blackfan anaemia were steroid responsive. One with transient erythroblastopenia was retrospectively diagnosed because anaemia did not recur after steroids were stopped. Transient erythroblastopenia is the most common single cause of red cell aplasia in immunocompetent children. Time, observation and bone marrow examination before steroid therapy are the ways to distinguish transient erythroblastopenia from Diamond Blackfan anaemia or leukaemia. Interpretation of red cell indices using age-related percentiles may reduce the number of inappropriate investigations of the anaemia, but is often unhelpful in distinguishing the various causes of red cell aplasia.

Entities:  

Mesh:

Year:  1993        PMID: 8482277     DOI: 10.1007/bf01956739

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  11 in total

1.  Seasonal clustering of transient erythroblastopenia of childhood.

Authors:  K Bhambhani; S Inoue; S A Sarnaik
Journal:  Am J Dis Child       Date:  1988-02

2.  Transient erythroblastopenia in the first year of life.

Authors:  R E Ware; T R Kinney
Journal:  Am J Hematol       Date:  1991-07       Impact factor: 10.047

3.  Differentiation of transient erythroblastopenia of childhood from congenital hypoplastic anemia.

Authors:  W C Wang; W C Mentzer
Journal:  J Pediatr       Date:  1976-05       Impact factor: 4.406

4.  Human parvovirus induced cytopenias: a report of five cases.

Authors:  P W Saunders; M M Reid; B J Cohen
Journal:  Br J Haematol       Date:  1986-06       Impact factor: 6.998

5.  Transient erythroblastopenia of childhood. A review of 26 cases and reassessment of indications for bone marrow aspiration.

Authors:  T Hays; P A Lane; F Shafer
Journal:  Am J Dis Child       Date:  1989-05

Review 6.  Hematologic and hematopoietic consequences of B19 parvovirus infection.

Authors:  N Young
Journal:  Semin Hematol       Date:  1988-04       Impact factor: 3.851

Review 7.  Human parvoviruses.

Authors:  L J Anderson
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

8.  Fetal-like erythropoiesis during recovery from transient erythroblastopenia of childhood (TEC).

Authors:  M P Link; B P Alter
Journal:  Pediatr Res       Date:  1981-07       Impact factor: 3.756

Review 9.  Biological activities and potential therapeutic uses of steel factor. A new growth factor active on multiple hematopoietic lineages.

Authors:  S D Lyman; D E Williams
Journal:  Am J Pediatr Hematol Oncol       Date:  1992

10.  Transient erythroblastopenia of childhood: varied pathogenesis.

Authors:  M H Freedman; E F Saunders
Journal:  Am J Hematol       Date:  1983-05       Impact factor: 10.047

View more
  3 in total

Review 1.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 2.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

3.  The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa.

Authors:  Chabo Byaene Alain; Lufimbo Katawandja Antoine; Bizeti Nsangu Bizette; Pambu Dahlia; Tshibuela Beya Dophie; Muwonga Masidi Jérémie; Kayembe Nzongola-Nkasu Donatien; Ahuka Mundeke Steve
Journal:  Pan Afr Med J       Date:  2020-03-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.